RAD51B germline pathogenic in EOC: confers HR deficiency. RAD51C and RAD51D have establis...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-RAD51B-GERMLINE-OVARIAN |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-CIVIC SRC-ESMO-OVARIAN-2024 SRC-NCCN-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | RAD51B germline pathogenic |
| Disease | DIS-OVARIAN |
| ESCAT tier | IIB |
| Recommended combinations | niraparib maintenance, olaparib + bevacizumab (HRD-positive), rucaparib maintenance |
| Evidence summary | RAD51B germline pathogenic in EOC: confers HR deficiency. RAD51C and RAD51D have established EOC risk; included in HRR panels and HRD-positive PARPi trial subgroups (PAOLA-1, ARIEL3 LOH-high, NOVA non-gBRCA). RAD51B less established. ESCAT IIA-IIB / OncoKB 3A-3B. |
Notes
Cascade testing per NCCN. RAD51B carriers also have moderate breast-cancer risk in relatives.
Used By
No reverse references found in the YAML corpus.